| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 15, 2012With Latest Certifications, Company’s Flagship DES Has Broadest Range of Approved Indications in Europe; Study Findings Presented at EuroPCR
PARIS--(BUSINESS WIRE)--May. 15, 2012-- As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European...
-
May 11, 2012Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 11, 2012-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in...
-
May 10, 2012Late-Breaking Clinical Trial Validates Medtronic Proprietary Device Algorithms
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
May 8, 2012Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries
MINNEAPOLIS--(BUSINESS WIRE)--May. 8, 2012-- Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant®...